These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 26864212)
1. Unveiling the "Three-Finger Pharmacophore" Required for p53-MDM2 Inhibition by Saturation-Transfer Difference (STD) NMR Initial Growth-Rates Approach. Angulo J; Goffin SA; Gandhi D; Searcey M; Howell LA Chemistry; 2016 Apr; 22(17):5858-62. PubMed ID: 26864212 [TBL] [Abstract][Full Text] [Related]
2. Ligand-receptor binding affinities from saturation transfer difference (STD) NMR spectroscopy: the binding isotherm of STD initial growth rates. Angulo J; Enríquez-Navas PM; Nieto PM Chemistry; 2010 Jul; 16(26):7803-12. PubMed ID: 20496354 [TBL] [Abstract][Full Text] [Related]
3. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy. Shin JS; Ha JH; Chi SW Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622 [TBL] [Abstract][Full Text] [Related]
4. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. Showalter SA; Bruschweiler-Li L; Johnson E; Zhang F; Brüschweiler R J Am Chem Soc; 2008 May; 130(20):6472-8. PubMed ID: 18435534 [TBL] [Abstract][Full Text] [Related]
5. Protein-ligand structure determination with the NMR molecular replacement tool, NMR Orts J; Riek R J Biomol NMR; 2020 Nov; 74(10-11):633-642. PubMed ID: 32621003 [TBL] [Abstract][Full Text] [Related]
6. NMR structure of a complex between MDM2 and a small molecule inhibitor. Fry DC; Emerson SD; Palme S; Vu BT; Liu CM; Podlaski F J Biomol NMR; 2004 Oct; 30(2):163-73. PubMed ID: 15557803 [TBL] [Abstract][Full Text] [Related]
7. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins. Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548 [TBL] [Abstract][Full Text] [Related]
8. Characterizing the Free-Energy Landscape of MDM2 Protein-Ligand Interactions by Steered Molecular Dynamics Simulations. Hu G; Xu S; Wang J Chem Biol Drug Des; 2015 Dec; 86(6):1351-9. PubMed ID: 26032728 [TBL] [Abstract][Full Text] [Related]
9. Saturation transfer difference NMR spectroscopy as a technique to investigate protein-carbohydrate interactions in solution. Haselhorst T; Lamerz AC; Itzstein Mv Methods Mol Biol; 2009; 534():375-86. PubMed ID: 19277538 [TBL] [Abstract][Full Text] [Related]
10. Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. Rothweiler U; Czarna A; Krajewski M; Ciombor J; Kalinski C; Khazak V; Ross G; Skobeleva N; Weber L; Holak TA ChemMedChem; 2008 Jul; 3(7):1118-28. PubMed ID: 18428185 [TBL] [Abstract][Full Text] [Related]
11. NMR screening for lead compounds using tryptophan-mutated proteins. Rothweiler U; Czarna A; Weber L; Popowicz GM; Brongel K; Kowalska K; Orth M; Stemmann O; Holak TA J Med Chem; 2008 Aug; 51(16):5035-42. PubMed ID: 18680271 [TBL] [Abstract][Full Text] [Related]
12. Inhibitors of MDM2 and MDMX: a structural perspective. Riedinger C; McDonnell JM Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995 [TBL] [Abstract][Full Text] [Related]